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Background: Cocaine use continues to be a public health problem, yet there is no proven 
effective pharmacotherapy for cocaine dependence. A promising approach to treating cocaine 
dependence may be agonist-replacement therapy, which is already used effectively in the treat-
ment of opioid and tobacco dependence. The replacement approach for cocaine dependence posits 
that administration of a long-acting stimulant medication should normalize the neurochemical 
and behavioral perturbations resulting from chronic cocaine use. One potential medication to 
be substituted for cocaine is methylphenidate (MPH), as this stimulant possesses pharmacobe-
havioral properties similar to those of cocaine.
Aim: To provide a qualitative review addressing the rationale for the use of MPH as a cocaine 
substitute and its clinical potential in the treatment of cocaine dependence.
Methods: We searched MEDLINE for clinical studies using MPH in patients with cocaine abuse/
dependence and screened the bibliographies of the articles found for pertinent literature.
Results: MPH, like cocaine, increases synaptic dopamine by inhibiting dopamine reuptake. 
The discriminative properties, reinforcing potential, and subjective effects of MPH and cocaine 
are almost identical and, importantly, MPH has been found to substitute for cocaine in animals 
and human volunteers under laboratory conditions. When taken orally in therapeutic doses, 
its abuse liability, however, appears low, which is especially true for extended-release MPH 
preparations. Though there are promising data in the literature, mainly from case reports and 
open-label studies, the results of randomized controlled trials have been disappointing so far and 
do not corroborate the use of MPH as a substitute for cocaine dependence in patients without 
attention deficit hyperactivity disorder.
Conclusion: Clinical studies evaluating MPH substitution for cocaine dependence have provided 
inconsistent findings. However, the negative findings may be explained by specific study charac-
teristics, among them dosing, duration of treatment, or sample size. This needs to be considered 
when discussing the potential of MPH as replacement therapy for cocaine dependence. Finally, 
based on the results, we suggest possible directions for future research.
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Introduction
Since the 1980s, the use of cocaine has emerged as a significant public health problem 
globally. According to the United Nations Office on Drugs and Crime (UNODC), in 
2012 there were 17 million cocaine users (range 13–20) worldwide.1 Cocaine has been 
estimated to be the second most used illicit drug in North and South America, the 
 Caribbean, Southern Africa, and Western and Southern Europe.2,3 In Europe, cocaine 
is the most popular illicit stimulant drug. It is estimated that approximately 2.2  million 
young adults aged 15–34 years (1.7% of this age group) used cocaine in the last year.3 
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However, as elsewhere in the world, there is great variability 
across Europe; high estimates of cocaine use are restricted to a 
number of countries, with UK, Spain, Ireland, the  Netherlands, 
and Denmark ranking at the top concerning prevalences of 
lifetime and past-year cocaine use.3  Wastewater analyses from 
42 cities also revealed large regional differences in cocaine 
use in Europe.4  Considering longer-term trends in cocaine 
use, declines have been observed after a peak in 2008 for 
most European countries, especially for those where cocaine 
use is widespread.3
Cocaine use is associated with a variety of psychiatric 
conditions and with negative physical and psychosocial 
consequences.5 Among others, these include cardiovascular 
and neurological disorders, psychotic symptoms, blood-
borne infections (eg, HIV, HBV, HCV), unintentional inju-
ries, violent behaviors, and premature death.6–12 According 
to epidemiological data, cocaine users show a four-to-eight 
times higher mortality rate than their age–sex peers in 
the general population.13 Although many consumers use 
cocaine occasionally, some develop a more compulsive 
pattern of use and become dependent on cocaine. It has 
been estimated that 6%–7% of those who use cocaine for 
the first time will develop a dependence syndrome within 
the first year of use and about one-fifth will meet depen-
dence criteria by the age of 45 years.14 Cocaine dependence 
is a chronic mental disorder characterized by high rates 
of relapse, which may occur after many months or even 
years of abstinence. It has a significant impact because 
of its onset in younger age and contributes substantially 
to burden of disease.15 Cocaine accounts for a substantial 
proportion of treatment admissions for substance use 
disorders.  According to the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA), cocaine was 
cited as the primary drug for 14% of all reported persons 
entering specialized drug treatment in 2012 (55,000), and 
18% of those entering treatment for the first time (26,000).3 
Differences exist between countries, with approximately 
90% of all cocaine patients being reported by Germany, 
Spain, Italy, the Netherlands, and the UK, which account 
together for just over half of the EU population.
Comorbid attention def icit hyperactivity disorder 
(ADHD) is common among cocaine-dependent patients, 
and substance-using patients in general.16,17 Furthermore, 
substance use is prevalent in parents of children with 
ADHD,18 and children of substance-using adults are at an 
elevated risk for ADHD.19 Dopaminergic deficits as well 
as executive dysfunction have been demonstrated in both 
disorders,20,21 which may share common genetic risk factors.22 
Individuals may also, at least initially, use cocaine as self-
medication for symptoms related to ADHD.23
Current status of treatment  
for cocaine dependence
The treatment of cocaine dependence still remains a great 
challenge. After almost 3 decades of intense research, there is 
no well-established effective medication available, nor is any 
medication approved for cocaine dependence by any medica-
tion’s regulatory authority. The primary interventions with 
evidence of efficacy are behavioral approaches. For instance, 
contingency management (CM) which provides incentives 
(eg, vouchers, cash) for drug-free urine samples or other 
desired behaviors (eg, treatment attendance) has proven effec-
tive in reducing cocaine use and fostering abstinence during 
treatment, even in difficult-to-treat patients.24,25 However, it 
is not clear whether CM leads to long-term abstinence, as its 
effects tend to subside after treatment.24,26 Another effective 
intervention for patients committed to reducing or eliminating 
their cocaine use is cognitive-behavioral therapy (CBT).27,28 
Its goal is abstinence through functional analysis of high-risk 
situations for cocaine use and the development of effective 
coping strategies through skills training. Yet, the impact 
of behavioral approaches is limited for several  reasons. 
Among others, they require substantial investments in care 
delivery systems and trained professionals to implement 
the interventions.29 Moreover, cognitively more demanding 
interventions, such as CBT, do not suit all patients,30,31 and 
patient commitment is important for CBT success.32–34 Over-
all, behavioral treatments alone have moderate effect sizes 
in terms of abstinence and retention,27,28,35 underscoring the 
continuing need for effective pharmacotherapies for cocaine 
dependence.27,36
One plausible pharmacotherapeutic approach to treat 
cocaine dependence is agonist-replacement, or substitution, 
therapy, which is already effectively used in the treatment of 
opioid37,38 and tobacco39,40 dependence. As the term implies, a 
pharmacologically similar agent is thereby substituted for the 
abused substance with the goal to reduce the cycle of compul-
sive substance use and its associated harms. This qualitative 
review addresses the rationale for the use of methylphenidate 
(MPH) as a substitution medication and its clinical potential 
for the treatment of cocaine dependence.
Methods
We performed a MEDLINE search using the following key 
terms (all without quotation marks): “cocaine use”, “treat-
ment”, all in combination with the term “methylphenidate” 
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and the Boolean operator “AND”. The search produced 
144 results published from 1965 through September 2014. 
Two of the authors also scanned the references of the stud-
ies to identify additional citations that were not captured in 
the search. For the review, we included studies on treatment 
of patients with cocaine abuse/dependence with MPH to 
improve cocaine use. With this strategy, we identified eight 
case reports/open-label studies and six randomized controlled 
studies. In addition, we selectively considered preclinical and 
human laboratory data where appropriate.
Rationale for MPH as a potential 
substitute for cocaine
The replacement approach for cocaine dependence posits 
that substitution with a cross-tolerant agent may suppress 
cocaine craving and withdrawal symptoms and/or block the 
euphorigenic effects of cocaine.41,42 Ideally, such a com-
pound would mimic the positive effects of cocaine without 
inducing craving, ie, should likely have a slow onset and 
long duration of action to minimize drug abuse liability.41,43 
However, substitution therapies may also function as positive 
reinforcers and can therefore be used as reinforcing stimuli 
in CM strategies to decrease cocaine use and promote more 
adaptive behaviors.44
A valid target for a cocaine substitute is the dopamine 
system, as cocaine is thought to exert its reinforcing prop-
erties primarily by blockade of the presynaptic dopamine 
 transporters.45 This inhibits dopamine reuptake, elevating 
extracellular dopamine levels within the mesolimbic “reward” 
system, especially in the nucleus accumbens.45–47 While acute 
inhibition of dopamine uptake by cocaine consistently results 
in increased dopamine activity, chronic cocaine intake leads to 
dysregulation of striatal dopamine signaling.48–50 Compounds 
that directly or indirectly modulate dopamine to reverse altera-
tions associated with cocaine use may therefore prove benefi-
cial as treatment agents.51 However, though likely necessary, 
enhancement of the dopamine system may not be sufficient 
to treat cocaine dependence,52,53 as other neurotransmitter 
systems such as serotonin and norepinephrine mediate the 
reinforcing effects of cocaine.54
MPH
MPH, a piperidine derivate, was first synthesized in 1944 
and marketed by Ciba-Geigy Pharmaceutical Company 
as  Ritalin.55 Initially indicated for various conditions (eg, 
chronic fatigue, depressive states, disturbed senile behavior, 
or psychosis associated with depression),56 MPH is mainly 
used today for the treatment of ADHD and, to a lesser extent, 
sleep disorders (eg, excessive daytime sleepiness, narco-
lepsy).42 When used as indicated, this stimulant drug is well 
tolerated and remarkably safe with a minimal side effect 
profile as demonstrated in disparate patient populations,56,57 
especially also in those with ongoing cocaine use.31,58–60 In 
line with the stimulant-like effect profile of MPH, common 
side effects include insomnia, decreased appetite, dry mouth, 
increased heart rate, headache, nervousness, nausea, and diz-
ziness.31,55 Where potentially more serious side effects occur, 
they have been found to be reversible with dose reduction or 
drug discontinuance.56,61 Today, various immediate-release 
(IR) and sustained-release (SR) preparations of MPH are 
available under several brand names in multiple forms for 
oral and transdermal administration.
It is well established that MPH enhances cognitive perfor-
mance not only in individuals with ADHD or those who have 
suffered traumatic brain injury, but also in healthy human volun-
teers, eg, on tasks that are sensitive to frontal lobe damage.56,62,63 
In line with this, MPH has been found to improve higher-order 
aspects of neurocognitive functioning in cocaine-dependent 
individuals.63–65 This suggests that MPH therapy could poten-
tially reverse neural alterations and cognitive deficits result-
ing from chronic cocaine use, thereby making patients more 
amenable to behavioral interventions.66 The wake-promoting 
properties may also be positive in cocaine-using individuals, 
in particular regarding the known deterioration in sleep archi-
tecture associated with acute cocaine abstinence.67
However, MPH, like amphetamine and cocaine, can 
also elicit reinforcing effects and tolerance. Thus, it has 
the potential for abuse, misuse/diversion, and dependence, 
which limits its clinical use.68–70 While its abuse potential 
appears low when administered as indicated, which is 
especially the case for SR formulations, the misuse and 
diversion of MPH seems a more widespread problem.71–73 
Usually, this misuse is associated with efforts to increase 
concentration and attention, often in competitive academic 
environments.74,75
Neurochemical profile of MPH
Although MPH is structurally related to amphetamine, the 
two stimulants differ in their neurochemical mechanisms 
of action.76 Amphetamine causes dopamine release into 
the synaptic cleft and secondarily blocks catecholamine 
reuptake.77–79 In contrast, MPH, like cocaine, acts as a 
monoamine reuptake inhibitor; it binds to presynaptic 
dopamine and noradrenaline transporters, thereby increas-
ing the extracellular catecholamine concentrations.45,80–82 
However, the monoaminergic pharmacology of MPH and 
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cocaine is profoundly different from that of conventional 
monoamine reuptake inhibitors (eg, bupropion, mazindol).83 
Based on a wealth of data, Heal et al83 have recently con-
cluded that the unusual, stimulant profile of MPH and 
cocaine is not mediated by reuptake inhibition alone. They 
propose that MPH allosterically modulates the function of 
the dopamine reuptake transporter to reverse its direction 
of transport, resulting in a firing-dependent retrotransport 
of dopamine into the synaptic cleft. Cocaine and MPH 
may therefore act as “inverse agonists” of the dopamine 
transporter (DAT), and this mechanism may be the major 
contributor to their pharmacobehavioral actions, especially 
when given at high doses and by routes that promote rapid 
entry into the brain.
Although the exact mechanism by which cocaine and MPH 
exert their euphorigenic effects is not fully clear, brain imaging 
studies have shown that both drugs are very similar in terms of 
their action at the DAT.84–86 When administered intravenously, 
the in vivo potency of MPH at the DAT in the human brain 
is equivalent to that of cocaine.87 Moreover, the spatial and 
temporal distributions of intravenous (iv) MPH in the human 
brain are almost identical to those of iv cocaine, with the 
striatum showing the highest concentrations and time to reach 
peak uptake corresponding to 2–10 minutes for both drugs.88 
Although the effects of iv MPH and cocaine overlapped con-
siderably in that latter study, the two drugs differed markedly in 
their pharmacokinetics. The peak concentration of MPH in the 
brain was maintained for 15–20 minutes, whereas for cocaine it 
was maintained only for 2–4 minutes. MPH also cleared much 
more slowly from the striatum than did cocaine, with half-peak 
clearance of MPH taking about four to five times longer than 
that of cocaine (20 minutes). For both drugs, the fast uptake 
in the striatum paralleled the “high” experience but only for 
cocaine did the decline in the “high” correspond to the brain 
clearance rate. In contrast, for MPH, the “high” decreased as 
rapidly as for cocaine despite significant striatal binding of the 
drug, suggesting that acute tolerance to the reinforcing effects 
of MPH had occurred. The slow brain clearance of MPH may 
therefore limit its abuse potential, which would be favorable 
for a cocaine substitute.89 However, study data indicate that 
even when 80% of the DAT sites are occupied by MPH, this 
blockade does not prevent the subsequent “high” induced by a 
second iv injection of MPH given 60 minutes later.90
According to the rate hypothesis, the strength of euphori-
genic effects is proportional to the rate of drug binding to its 
site of action; thus, routes of administration which produce 
faster brain uptake are more reinforcing.91 MPH has been 
found to be up to 100-fold more potent when administered 
intravenously than orally.83 In brain imaging studies that 
evaluated the relationship between MPH-induced dopamine 
increases and their reinforcing effects when equivalent levels 
were established for iv and oral MPH, only iv MPH elicited 
a “high”.92,93 The peak level of DAT blockade for clinically 
relevant doses of MPH, although delayed at approximately 1 
hour, was about the same as that observed with iv MPH that 
induced a “high”.94 However, even when doses of iv MPH 
are administered that produce significant DAT blockade, 
they are not always perceived as reinforcing, suggesting 
that DAT blockade, although necessary, is not sufficient to 
produce the “high”.92
Behavioral effects profile of MPH
Preclinical and human laboratory studies suggest that the 
stimulant-like behavioral effects of MPH are virtually 
indistinguishable from those induced by cocaine when both 
drugs are delivered by the same route of administration. For 
example, both drugs function as reinforcers in animals and 
humans under a variety of laboratory conditions.68 When 
delivered intravenously, MPH, like cocaine, maintains 
high rates of operant responding in rats, and long access to 
MPH results in an escalation of intake similar to cocaine.95 
 Injections of iv MPH also sustain self-administration in squir-
rel monkeys.96 Furthermore, drug discrimination studies in 
rodents indicate that MPH at higher doses fully substitutes 
for the cocaine cue.52,97 In laboratory studies examining the 
reinforcing effects of cocaine in rats pretreated with intra-
peritoneal MPH, higher doses of MPH decreased cocaine 
intake but not responding to cocaine.97 However, 8-month 
treatment with oral MPH significantly reduced the rates of 
cocaine self-administration in rodents, suggesting that MPH 
pretreatment may alter cocaine reinforcement.98
With respect to the euphorigenic properties of MPH, 
subjective-effects studies of oral MPH in human adults 
have provided mixed results. In some studies, single doses 
up to 60 mg MPH tended to increase ratings of activity, 
arousal, concentration, intellectual efficiency, energy, anxi-
ety, and talkativeness in healthy volunteers with no history 
of substance dependence, but not those of “drug liking”, 
“euphoria”, or “high”.94,99,100 Other studies, in contrast, 
found increased ratings of “good effects” and “drug liking” 
in non-drug-using volunteers after administration of oral 
MPH 40 mg.71,101–103 However, SR formulations of MPH are 
associated with less or lower ratings of “good effects” as 
compared to the IR formulation.71
In laboratory studies with cocaine-experienced volunteers, 
oral MPH 15–90 mg also produced ratings of “drug liking” 
and “stimulation” similar to those reported for oral cocaine.104 
Moreover, single doses of intranasally administered MPH 
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(10, 20, 30 mg) yielded dose-dependent increases in ratings 
of “good effects” and “high” in recreational stimulant users.105 
After injections of iv MPH (0.5 mg/kg), both drug-naïve and 
cocaine-using volunteers experienced a “high”.106 Cocaine 
users reported that the “high” induced by iv MPH was similar 
to that of iv cocaine but lasted longer and was associated with 
more physical effects, ie, “stimulated more the body than the 
brain”.106 MPH injections also consistently induced cocaine 
craving in these cocaine users, while, in another experiment, 
oral IR MPH doses up to 60 mg increased neither cocaine 
craving nor subjective ratings that could suggest abuse poten-
tial in cocaine-dependent participants.107 Furthermore, oral 
MPH in supratherapeutic doses was found to generalize to 
the cocaine cue in cocaine users who have been trained to 
discriminate between placebo and 200 mg oral cocaine; 
relatively high rates of cocaine-appropriate responding were 
also observed with MPH 30 mg.104
In two human laboratory studies assessing the effects 
of MPH treatment on iv cocaine,58,60 cocaine-dependent 
volunteers with and without adult ADHD were maintained 
on 0, 40, and 60 mg/day or on 0, 60, and 90 mg/day oral 
SR MPH. Both of these studies included a fixed cocaine 
dosing schedule. During each maintenance phase, a 
dose–response function was determined for iv cocaine 
(0–50 mg).  Maintenance on MPH significantly attenuated 
cocaine-induced increases in “good effects” and “desire 
for cocaine” ratings; these effects, however, were limited 
to the lower cocaine doses. In addition to the fixed dos-
ing of cocaine, the first of these studies also included a 
choice experiment, in which seven cocaine-dependent 
patients with concomitant ADHD were maintained on 0, 
40, and 60 mg/day oral SR MPH.58 The reinforcing effects 
of iv cocaine (0, 16, and 48 mg/70 kg) were assessed 
using a procedure wherein participants sampled a dose 
of iv cocaine (16 or 48 mg/70 kg) and were then given 
five opportunities to choose between it and two tokens, 
each exchangeable for US$2. As compared to placebo 
treatment, substitution with 60 mg/day MPH reduced 
the choice of the higher iv dose significantly from four 
to two times.
Overall, clinical laboratory studies largely support MPH 
as a treatment for cocaine addiction. To our knowledge, how-
ever, there are no studies on how cocaine users experience 
MPH in naturalistic settings.
Clinical studies on MPH as a 
substitute for cocaine
A number of case reports, open-label studies, and controlled 
trials have addressed the clinical potential of MPH for the 
treatment of cocaine dependence in various patient popula-
tions (Table 1).
Case reports
Khantzian23 was the first to report a case of a woman who 
presented a childhood history suggestive of ADHD and 
whose chronically excessive cocaine use was endangering 
her life. He started her on MPH 15 mg three times per 
day (tid) after a 6-day cocaine binge that had ended only 
5 hours prior to her therapy appointment. Within 1 day, 
she began to experience normal appetite and sleep. Her 
mood had improved significantly and her cocaine craving 
had  disappeared. She experienced one minor relapse in the 
first year as confirmed by urinalysis and continued weekly 
therapy sessions. A 2-year follow-up of this patient was 
presented 1 year later as the case of “Mrs B” in a series 
of case reports108 that described three cocaine-dependent 
patients who shortly after beginning treatment with MPH 
showed a reduction in cocaine use. Medication was 
started at 15 mg tid in two patients and 5 mg four times 
per day in one patient. Doses were then increased up to 
a maximum of 70 mg/day. All three patients remained 
abstinent from cocaine for at least several months up to 
2 years. Moreover, MPH improved symptoms of depres-
sion in one patient; in another, enhanced concentration 
and less violent behavior was stated; and, in the third 
patient, agitation, compulsive gambling, and interest in 
pornography decreased. The authors concluded that these 
cases lent support to the self-medication hypothesis of 
Khantzian.23 This hypothesis posits that an individual’s 
choice to use a particular drug depends to some degree on 
the drug’s effect on subjective painful affects or unpleas-
ant emotional states which may or may not be associated 
with a psychiatric disorder.23
Two other successful case reports have appeared more 
recently. Imbert et al109 report the case of a male patient with 
cocaine dependence and adult ADHD who was also addicted 
to gambling and compulsive sex. Medication with the aim of 
improving ADHD symptoms and cocaine dependence was 
started with SR MPH 18 mg/day and increased to 54 mg/day. 
ADHD symptoms decreased after 2 weeks and craving for 
cocaine disappeared after 1 month of treatment. The patient 
stayed abstinent from cocaine and alcohol and quit gambling 
and compulsive sex, as shown in a 1-year follow-up. The other 
report110 depicts the case of a cocaine- and alcohol-dependent 
borderline illiterate man with difficulties in attention, rest-
lessness, and hyperactivity during childhood. Treatment was 
started with SR MPH 36 mg/day and reduced to 27 mg/day. 
The patient described the treatment as “a miracle” since he 
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Table 1 Overview of case reports and clinical trials addressing methylphenidate as a treatment for cocaine dependence
Author  
(year)
Participants Intervention Outcome measures Findings
Case reports
Khantzian  
(1983)23
One female outpatient  
with childhood history  
indicative of ADHD
MPH starting dose 15 mg tid Urinalysis, self-reports MPH effective in reducing cocaine 
use
Khantzian  
et al (1984)108
Three patients (one  
female, two male),  
one male with ADHD
MPH starting dose 15 mg tid or  
5 mg qid, max 70 mg/day
Urinalysis, self-reports MPH effective in reducing cocaine 
use
imbert  
et al (2014)109
One male outpatient  
with adult ADHD
SR MPH starting dose 18 mg/day,  
increased to 54 mg/day
Urinalysis, clinical  
examination, CCQ-Brief
MPH effective in reducing cocaine 
use
Mariani  
et al (2014)110
One male outpatient SR MPH starting dose 36 mg/day,  
decreased to 27 mg/day
Urinalysis, self-reported  
cocaine use
MPH effective in reducing cocaine 
use
Gawin  
et al (1985)111
Five male patients  
without ADHD
MPH starting dose 20 or 40 mg/day,  
max 100 mg/day
Self-reported cocaine  
craving and use
MPH not effective, increased 
cocaine use and craving
Open-label trials
Levin  
et al (1998)112
12 outpatients with  
adult ADHD
SR MPH doses from 20 to 40 mg bid Urinalysis (tiw), ASi, side  
effects checklist, cocaine- 
craving questionnaire
MPH effective in reducing cocaine 
use; eight patients completed the 
study
Castaneda  
et al (1999)113
19 private patients  
with adult ADHD  
(17 males)
Fluoxetine 20 mg# 
Bupropion 100 mg 
Pemoline 37.5 mg 
SR MPH 20 mg 
Dextroamphetamine 10 mg 
Methamphetamine 15 mg
Urinalysis (qw or biw) LA stimulants alone or in 
combination with fluoxetine or 
bupropion most effective
Somoza  
et al (2004)114
41 outpatients with  
adult ADHD
iR MPH starting dose 20 mg/day,  
max 20 mg tid
Urinalysis (tiw), CGi,  
ASi, Substance Use  
Questionnaire, BSCS,  
CCQ-GeN, vital signs  
and adverse events,  
retention in treatment
MPH effective in compliant 
patients; 70% completed the study
Double-blind, randomized, placebo-controlled studies
Levin  
et al (2007)118
106 outpatients  
with adult ADHD  
(83% males)
1.  iR MPH starting dose 10 mg/day,  
SR MPH max 60 mg/day (40 mg am,  
20 mg pm); n=53
2. Placebo; n=53
Urinalysis (tiw),  
self-reports, retention  
in treatment
MPH reduced likelihood of cocaine 
use over time; 23 patients of 
group 1 and 24 patients of group 2 
completed the study
Grabowski  
et al (1997)59
49 outpatients without 
ADHD
1.  MPH 45 mg/day (5 mg iR and  
20 mg SR MPH am, 20 mg SR pm);  
n=25
2. Placebo; n=24
Urinalysis (biw), ASi,  
SeQ, retention  
in treatment
No advantage of MPH over placebo 
in reducing cocaine use;  
48% of group 1 and 42% of  
group 2 completed the study
Schubiner  
et al (2002)61
48 outpatients  
with adult ADHD  
(43 males)
1. MPH 30 mg/tid; n=24 
2. Placebo; n=24
Urinalysis (tiw), ASi,  
CCQ-GeN, self-reports,  
side effects checklist, 
retention in treatment
No advantage of MPH over placebo 
in reducing cocaine use;  
45% of group 1 and 58% of  
group 2 completed the study
Levin et al  
(2006)117
98 methadone- 
maintained outpatients 
with adult ADHD  
(57% males)
1.  iR MPH starting dose 5 mg/bid,  
SR MPH max 40 mg/bid; n=32
2. SR bupropion max 400 mg/day; n=33 
3. Placebo; n=33
Urinalysis (tiw),  
self-reports, retention  
in treatment
No advantage of active medications 
over placebo in reducing cocaine use; 
21 patients of group 1, 23 patients of 
group 2, and 25 patients of group 3 
completed the study
Dürsteler- 
MacFarland  
et al (2013)31
62 diacetylmorphine- 
maintained outpatients  
(40 males)
1. iR MPH 30 mg bid + CBGT; n=15 
2.  iR MPH 30 mg bid + treatment  
as usual; n=15
3. Placebo + CBGT; n=17 
4. Placebo + treatment as usual; n=15
Urinalysis (tiw),  
self-reports, adverse  
effects, retention  
in treatment
No advantage of MPH over 
placebo in reducing cocaine use, no 
additive effects of MPH and CBT; 
71% completed the study with no 
between-group differences
Note: #Medications were introduced in an order inversely related to their expected degree of stimulant effects and were replaced when the medication did not substantially 
improve ADHD symptoms after 2 weeks or after having doubled the dose.
Abbreviations: ADHD, attention deficit hyperactivity disorder; ASI, Addiction Severity Index; bid, two times per day; biw, two times per week; BSCS, Brief Substance 
Craving Scale; CBGT, cognitive-behavioral group therapy; CBT, cognitive-behavioral therapy; CCQ-Brief, Cocaine Craving Questionnaire-Brief; CCQ-GeN, Cocaine Craving 
Questionnaire-General; CGi, Clinical Global impression Scale; iR, immediate-release; LA, long-acting; MPH, methylphenidate; qid, four times per day; qw, once per week; 
SeQ, Side effects Questionnaire; SR, sustained-release; tid, three times per day; tiw, three times per week.
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felt much better after only 1 day of medication. Apart from 
one minor slip, the patient had stayed abstinent from cocaine 
for 8 months at the time of writing the report.
In another series of case reports,111 five male cocaine users 
without ADHD received MPH to treat cocaine dependence. 
MPH was started at doses of 20 or 40 mg/day, which were 
individually increased up to 100 mg/day. MPH treatment 
lasted between 2 and 5 weeks before it was discontinued in 
all patients due to increased cocaine craving and use. Initially, 
most patients experienced a short duration of positive medi-
cation effects, but they rapidly built up tolerance to MPH. 
Furthermore, patients stated that MPH lacked the desired 
“rush”, which might also have led to the increased cocaine 
craving and use. The authors concluded that treatment with 
MPH is not successful in cocaine-dependent patients without 
comorbid ADHD.
Open-label studies
The first open-label study that investigated the effective-
ness of MPH as treatment for both cocaine use and ADHD 
included 12 cocaine-dependent outpatients with adult 
ADHD.112 Doses from 40 to 80 mg/day were used in this 
12-week study, in which ten participants remained for at least 
8 weeks, while eight of them completed the study. The most 
common side effects reported were dry mouth, increased 
heart rate, agitation, and jitteriness. No participant discon-
tinued the study due to side effects. Participants showed 
significant improvement in all ADHD symptoms (except 
mood lability) of almost 50% on psychometric measures. 
Cocaine craving and use had decreased significantly when 
the first 2 study weeks were compared to the last 2 weeks. 
Seven of the eight study completers were reachable for a 
follow-up 3 months later: three who still received MPH 
were cocaine-abstinent, as were two who were no longer 
treated with MPH, while two provided cocaine-positive 
urine samples.
Castaneda et al113 addressed a subgroup of cocaine-
dependent patients who reported how cocaine had had a 
paradoxically calming effect on them at the beginning of their 
cocaine use. All these patients were diagnosed as having adult 
ADHD, which led the authors to conclude that these cocaine-
dependent patients might have self-medicated their ADHD 
symptoms with cocaine, for which they report additional 
evidence in their study. Nineteen outpatients with adult ADHD 
and cocaine dependence in full remission were enrolled to 
this year-long, open-label, prospective study, which aimed at 
minimizing the risk of medication abuse or cocaine relapse. 
Before treatment for ADHD could be started, patients had 
to be abstinent from cocaine for 6 months or longer. Several 
medications were introduced for ADHD treatment in an order 
inversely related to their expected degree of stimulant effects 
and were replaced when the medication did not substantially 
improve ADHD symptoms after 2 weeks or after having 
doubled the dose. Treatment was viewed as fully effective 
when it decreased initial ADHD symptoms for a minimum of 
12 months. Medications were administered in the following 
order and starting doses: fluoxetine 20 mg, bupropion 100 mg, 
pemoline 37.5 mg, SR MPH 20 mg, dextroamphetamine 
10 mg, and methamphetamine 15 mg. Therapy with a long-
acting stimulant (mostly SR MPH) alone or combined with 
fluoxetine or bupropion was most effective in suppressing 
ADHD symptoms. Fully effective treatment responses were 
achieved in 18 out of the 19 participants. The applied treatment 
strategy was found to be highly effective for treating ADHD 
symptoms, with cocaine use occurring only in four out of the 
19 patients (two slips, two relapses).
Somoza et al114 also hypothesized that MPH could be 
safely and effectively used for the treatment of individuals 
with comorbid ADHD and cocaine dependence (mostly 
crack use). IR MPH was started at 20 mg/day and increased 
to a dose of 20 mg tid. Of the 41 outpatients enrolled in 
this 10-week, open-label study, 19 were rated as being 
compliant due to MPH plasma levels and ratings of the 
staff. Seventy percent of the participants completed the 
study. A significant difference in study retention was found 
between compliant and noncompliant participants. MPH 
was concluded to be safe with a minimum of side effects 
which were not serious and did not persist on a moderate 
or severe rating. With respect to cocaine use, study results 
showed that only participants reported to be compliant 
benefited from MPH. Compared to 0% of the noncompliant 
participants, 37% of the compliant stayed abstinent from 
cocaine during the study. A comparison of baseline and 
endpoint ADHD measures, however, revealed that ADHD 
symptoms had improved significantly in all participants, 
irrespective of compliance.
Randomized controlled trials
Five double-blind, randomized, and placebo-controlled 
trials on the efficacy of MPH as replacement therapy for 
cocaine dependence have been published so far. One other 
randomized but single-blind trial115 was excluded from this 
review as its main focus does not lie on the management 
of cocaine dependence. Grabowski et al59 were the first to 
investigate this treatment approach in 49 cocaine-dependent 
outpatients with no other major mental health disorders who 
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were randomized to receive either MPH or a placebo. After 
a 2-week intake period, a dosage of MPH 45 mg/day was 
administered during the 11-week treatment phase. There 
was no between-group difference in study retention, with 
24 participants completing the trial. Study results showed 
no adverse effects of MPH and no increase of cocaine use. 
However, there was also no significant difference in cocaine 
use between the study groups; both groups continued to use 
cocaine. With respect to self-report items (eight items from 
Side Effects Questionnaire assessing direct drug effects) the 
two groups differed in the items “eating less”, “drowsy”, and 
“more energy”, suggesting that the MPH but not the placebo 
group noticed a direct effect of medication.
Dürsteler-MacFarland et al31 evaluated the feasibility, 
tolerability, and efficacy of MPH and cognitive-behavioral 
group therapy (CBGT) for cocaine dependence in patients 
prescribed diacetylmorphine. Sixty-two cocaine-dependent, 
diacetylmorphine-maintained patients participated in this 
dual-site, double-blind, placebo-controlled trial with four 
treatment arms. They were randomly assigned to receive 
MPH or placebo, each of which combined with either 
CBGT or treatment as usual for 12 weeks. After a baseline 
week, IR MPH 30 mg two times per day (bid) and placebo 
in identical capsules were administered under supervision. 
Manual-guided CBGT consisted of 12 weekly sessions in 
groups of five to seven patients. Primary outcome measures 
were cocaine-free urine samples, retention in pharmacologic 
treatment, and adverse effects. Urine cocaine screens were 
performed thrice weekly. Seventy-one percent of participants 
completed the trial. MPH was well tolerated with similar 
retention rates compared to placebo. No serious MPH-related 
adverse effects occurred. However, without reaching statisti-
cal significance, participants receiving MPH reported more 
side effects than those receiving placebo; these occurred at 
the beginning of the trial and disappeared soon after. The most 
common reported side effects were insomnia, dry mouth, 
hyperactivity, loss of appetite, and cardiac palpitations. 
There was a significant decline in self-reported amount and 
frequency of cocaine use in all groups, but data showed no 
significant change in cocaine-free urine samples. MPH did 
not provide an advantage over placebo in reducing cocaine 
use. In contrast to positive results obtained in other samples, 
this study does not support a role for CBGT for treating 
cocaine dependence in this patient group. There were no 
signs of additive benefits of MPH and CBGT.
ADHD is a common psychiatric comorbidity among 
cocaine-dependent individuals, with prevalence rates of up 
to 30% in some studies.116 Based on the self-medication 
hypothesis,23 other controlled trials have therefore evaluated 
the efficacy of MPH treatment for adult ADHD and comorbid 
cocaine dependence. The assumption hereby is that MPH might 
have a beneficial effect on ADHD symptoms which would also 
lead to a decline in cocaine use. Schubiner et al61 addressed 
this hypothesis in 48 cocaine-dependent patients with adult 
ADHD in a 12-week double-blind,  placebo-controlled trial 
after a baseline week. MPH doses were titrated from an initial 
dosage for the first 2 or 3 days (10 mg tid) to a second dosage 
level (20 mg tid) for the next 4 to 5 days to the target dose of 
MPH 30 mg tid by day 8. Retention in the study did not differ 
by group; 45% of the MPH and 58% of the placebo group 
completed the study. However, participants from the placebo 
group were less likely to drop out before the end of study week 
4 than those from the MPH group. Reported side effects were 
generally high before the medication phase and remained so 
throughout the trial. Intensity of insomnia and sadness in the 
MPH group were higher at baseline and during the study than 
in the placebo group. A dose reduction was required in 25% 
of the participants receiving MPH; however, none of them 
discontinued the trial due to adverse side effects. The study 
demonstrated the safety of supratherapeutic doses of MPH in 
cocaine-dependent patients with adult ADHD. Although MPH 
did not decrease cocaine use or craving, it improved subjective 
reports of ADHD symptoms as compared to placebo.
Levin et al117 compared the efficacy of SR MPH or SR 
bupropion to placebo in treating ADHD symptoms and 
additional cocaine use. The sample included 98 methadone-
maintained patients with adult ADHD, of whom 53% also 
met criteria for cocaine abuse or dependence. Participants 
were randomly assigned to the MPH, bupropion, or placebo 
treatment. The 12-week study duration included a 2-week 
lead-in phase with placebo, a 2-week titration phase, and 
8 weeks at stable doses. MPH was started at 5 mg bid with 
standard formula and increased to a maximum dose of SR 
MPH 40 mg bid. Bupropion was started at 100 mg/day 
and increased to a maximum dose of 200 mg bid. Overall, 
69 participants completed the study; the groups did not differ 
in retention rates. The results showed a reduction of ADHD 
symptoms in all three study groups. However, there were 
no significant group differences, suggesting that neither SR 
MPH nor SR BPR is more effective than placebo in treating 
ADHD symptoms in these patients. In terms of cocaine use, 
subgroup analysis demonstrated a high proportion of cocaine-
positive weeks across all groups throughout the trial, whereby 
active medication had no advantage over placebo in improv-
ing cocaine use. Nevertheless, no evidence of medication 
abuse was found and both medications were well tolerated 
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with no adverse side effects. The most common side effects 
were fatigue and increased sweating. No group differences 
were observed with respect to side effects.
Another double-blind trial by Levin et al118 hypothesized 
that treatment with MPH would lead to greater improvement 
of ADHD symptoms and cocaine use than placebo. The sam-
ple consisted of 106 adult ADHD outpatients with comorbid 
cocaine dependence who participated in this 14-week trial 
(1 week placebo lead in, 2-week titration phase, and 11 weeks 
of medication treatment). MPH was started at 10 mg/day 
standard formulation and increased to a maximum dose of 
60 mg/day of SR MPH (40 mg in the morning and 20 mg in 
the afternoon). Retention in treatment did not differ between 
groups. Eighty-nine participants, of whom 47 completed the 
trial, remained at least 4 weeks in the study. A variety of side 
effects were reported across both groups but there were no 
significant group differences. The most frequently reported 
side effects were headache, gastrointestinal upset, diarrhea, 
and insomnia. Most of the participants reported at least a 
30% decrease in ADHD symptoms. However, in contrast to 
Schubiner et al,61 this study did not find a significant differ-
ence between the groups. Although there was no substantial 
improvement in cocaine abstinence in either group, those 
receiving MPH had a reduced likelihood of cocaine use 
over time. A secondary analysis showed no improvement in 
cocaine use for participants in the placebo group, regardless 
of ADHD response. However, in the MPH group, the likeli-
hood of submitting cocaine-positive urine samples decreased 
by 36% over time for ADHD responders compared to under 
10% for ADHD nonresponders, suggesting a beneficial effect 
of MPH treatment in this group.
To summarize, all double-blind, placebo-controlled trials 
confirmed that the administration of up to MPH 90 mg/day 
to cocaine-dependent patients with or without adult ADHD 
and/or with simultaneous diacetylmorphine or methadone 
maintenance is safe and does not increase cocaine use or 
craving. However, in contrast to most open-label studies, 
the more rigorously controlled studies were not able to 
show a substantial decrease of cocaine use through MPH 
treatment.
Discussion
Overall, the findings from human laboratory and clinical 
studies assessing the clinical potential of MPH as an ago-
nist medication for cocaine dependence are inconclusive. 
Controlled laboratory studies have shown that MPH can be 
safely administered in combination with cocaine without 
relevant clinical consequences and that MPH substitution 
reduces some of the positive effects of cocaine.58,60,107 With 
one exception,111 the available case reports23,43,108,109 and open-
label studies112–114 also suggest that substitution with MPH 
might be a safe and effective treatment intervention in cocaine 
dependence, especially in those with comorbid ADHD. In 
contrast, randomized controlled trials do not provide evidence 
for the effectiveness of MPH as replacement therapy, at least 
in those patients who do not additionally suffer from ADHD; 
yet, they have demonstrated that MPH is well tolerated and 
remarkably safe with minimal side effects in active cocaine 
users.31,59,61,117,118 However, there are several explanations for 
the negative results of these trials which should be consid-
ered when discussing the potential of MPH as a substitution 
therapy for cocaine dependence and planning further studies. 
The negative findings may in part be due to relatively small 
sample sizes, the dose and formulation of MPH used, the 
duration of MPH treatment and time point of its initiation, 
as well as patient characteristics.
A general problem of randomized controlled trials is 
that there are upper limits of dosing. These limits may not 
adequately approximate the cocaine use patterns in natural-
istic settings. The MPH doses administered in the trials so 
far might be too small to be effective. In fact, laboratory data 
indicate that higher doses of MPH more effectively attenuate 
cocaine’s positive subjective effects and decrease choices for 
cocaine over money in cocaine users.58,60 Some evidence also 
suggests that chronic cocaine use decreases sensitivity to dop-
aminergic medications.49 This means that dosing at the high 
end of the recommended range or above would be required 
to be effective in cocaine dependence. These doses, however, 
might be much higher than those commonly used for the 
treatment of ADHD and may increase the risk for side effects 
and especially for severe adverse events.61,119 Even at dosages 
of 90 mg/day, MPH did not show advantage over placebo 
in terms of cocaine use.61 Hence, MPH in therapeutic doses 
may be best suited for low-to-moderate severity of cocaine 
dependence. Connected to the cocaine users’ decreased 
sensitivity to dopaminergic medications, the duration of 
treatment and the time point of treatment initiation may also 
be critical determinants for effectiveness. Time to maximal 
reduction in cocaine use can vary considerably and may take 
several months. Such a delay between treatment initiation 
with MPH and reduction in drug use has been reported for 
amphetamine-dependent participants receiving a terminal 
dose of 54 mg/day of extended-release MPH.120 In that study, 
18 weeks of MPH treatment were required to significantly 
reduce amphetamine use. Furthermore, treatment with MPH 
in randomized controlled studies was induced while partici-
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pants were using cocaine. A different approach would be to 
start MPH treatment after participants have achieved an initial 
period of abstinence from cocaine (eg, via CM intervention) 
and to assess time to relapse and relapse rates over a longer 
period of time.
A recent brain imaging study has found that deficient 
dopamine transmission in cocaine users is associated with 
failure to respond to behavioral treatment.121 If deficient 
dopamine transmission predicts poor response to behav-
ioral interventions, then MPH replacement therapy could 
potentially reverse this deficit.43 In fact, brain imaging data 
suggest that MPH may ameliorate various neural dysfunc-
tions in mesocorticolimbic regions and improve neurocogni-
tive deficits found in cocaine users.64,65,122–126 In one study, 
for example, a single oral dose of 20 mg MPH normalized 
hypoactivation in the anterior cingulate cortex and improved 
behavioral measures of response inhibition.123 Moreover, Li 
et al65 have shown that MPH in cocaine-dependent individu-
als is associated with robustly decreased reaction time in 
the stop signal task, suggesting improvements in inhibitory 
control. Cognitive improvements were thereby positively 
correlated with inhibition-related activation in the medial 
frontal cortex, an area associated with motor inhibitory 
control. MPH has also been found to attenuate brain reac-
tivity of cocaine-dependent participants to cocaine-related 
cues in a brain imaging study.126 These findings highlight 
another mechanism by which MPH might be beneficial in 
the treatment of cocaine dependence, as intact dopamine 
signaling is required for responding to natural and thera-
peutic contingencies.121 However, the potential of MPH to 
increase the effects of behavioral interventions warrants 
further well-designed studies.
Interestingly, MPH treatment in cocaine-dependent 
patients with ADHD who respond positively to the medica-
tion in terms of ADHD symptoms is associated with a sig-
nificantly greater increase in the number of  cocaine-negative 
urine samples compared to those who respond poorly.118 
It is well known that variability in drug pharmacokinet-
ics and pharmacodynamics are largely influenced by an 
individual’s genetic profile. Properly assessed genetically 
driven functional changes in the DAT could help deter-
mine which patients could benefit from MPH for cocaine 
dependence.51,127 Individuals with variable number tandem 
repeats of the SLC6Q3 gene 3′-untranslated region polymor-
phism of DAT1 have been found to have altered responses 
to drugs, with the 10/10 repeat responding poorly to MPH. 
An example of a study of a predictive genetic biomarker 
in cocaine dependence has recently been published,128 but 
there are no data available for MPH treatment in cocaine 
dependence.
Some randomized controlled trials31,117 described above 
were conducted in polysubstance users maintained on metha-
done or diacetylmorphine. This may have influenced the 
results; smaller doses of MPH may be less effective in poly-
drug users or effects of ongoing substance use and potential 
withdrawal symptoms may have interfered with the studies. 
However, opioid withdrawal symptoms should be minimized 
or absent in patients on stable opioid maintenance. Further-
more, concomitant use of other substances is highly prevalent 
in cocaine users, and this population should therefore be 
included in the research on the effectiveness of a substitution 
approach for cocaine addiction.
Several studies on cocaine dependence suggest a dif-
ferential treatment outcome by sex.129 Moreover, the men-
strual cycle and levels of gonadal hormones can influence 
dopamine function, subjective effects of stimulants, and 
responsiveness to potential treatments.130 Because, typically, 
cocaine dependence is more prevalent in males, female 
patients are less often enrolled in studies, and this is also 
the case for the studies described here. Correspondingly, the 
results may be more representative of male cocaine users. 
None of the studies on MPH in cocaine dependence reported 
sex-specific effects; however, the number of enrolled females 
may have been too small to conduct these analyses. Future 
studies should take sex-specific effects and menstrual cycle 
into account.
Although there is no evidence from randomized controlled 
trials that MPH is superior over placebo in reducing cocaine 
use in cocaine-dependent patients without ADHD, clinical 
experience suggests that MPH might be beneficial for some 
patients when treatment is appropriately tailored to the indi-
vidual patient.23,43,108,109 Therefore, substitution therapy with 
MPH appears to be viable, with risks outweighed by benefits in 
carefully selected, monitored, and motivated patients. In these 
cases, SR or newer extended-release preparations of MPH are 
generally to be preferred over IR formulations for purposes 
of behavioral safety. However, further research is required to 
determine optimal treatment models (initiation after achieving 
a period of cocaine abstinence or during active cocaine use), 
effective and safe doses, and length of treatment. From these 
points of view, further well-designed studies are needed to bet-
ter evaluate the clinical potential of MPH as possible treatment 
for cocaine dependence. Future trials should be conducted in 
larger samples of clinically and genetically well-characterized 
participants, over a longer duration and with higher doses of 
supervised MPH administration, best combined with CM, 
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likely the most robust behavioral intervention available for 
cocaine dependence followed by CBT.
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